Understanding the three-dimensional architecture of orphan G protein-coupled receptors could unlock entirely new categories of therapeutic targets, potentially expanding the druggable genome beyond current pharmaceutical reach. These enigmatic membrane proteins have resisted structural determination precisely because researchers lack the molecular keys—specific ligands—needed to stabilize them for crystallographic analysis. The GPR151 receptor represents a particularly intriguing case within this orphan family, given its expression patterns in neural tissues and potential connections to neurological function. Investigators have now successfully determined the atomic-level structure of GPR151 using a novel stabilization approach called NELiS (Nanobody-Enhanced Ligand-Independent Stabilization). This technique bypasses the traditional requirement for native ligands by employing engineered nanobodies that lock the receptor in a structurally stable conformation suitable for high-resolution imaging. The resulting structural data reveals distinctive binding pocket geometries and conformational features that differentiate GPR151 from well-characterized GPCR subfamilies. This breakthrough demonstrates how innovative stabilization methodologies can overcome fundamental technical barriers that have historically limited orphan GPCR research. The structural insights provide a foundation for rational drug design efforts targeting GPR151, though translating these findings into therapeutic applications will require extensive validation of the receptor's physiological roles and downstream signaling pathways. More broadly, the NELiS approach may prove applicable to dozens of other orphan GPCRs, potentially accelerating the pace of structure-based drug discovery for previously inaccessible targets. However, the clinical relevance of GPR151 modulation remains speculative until functional studies clarify its biological significance in human health and disease.